Bristol-Myers Squibb announced positive Phase 3 data for two drugs. admilparant showed statistically significant lung function benefit at 60 mg in IPF. RYZ101 improved progression-free survival in GEP-NETs after Lu177 failure. Both have favorable safety. Regulatory submissions planned.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
